AtriCure, Inc.
NASDAQAtriCure enters September having delivered one of the more striking single-month moves in the medtech space — a 30% gain in August to $48.92 — and the Street is now scrambling to catch up. The most telling development this week is the speed and scale of analyst target revisions. Needham lifted its target from $45 to $64 on September 2, keeping its Buy rating, while Piper Sandler…
Snapshot as of 2 Sept 2026
AtriCure enters September having delivered one of the more striking single-month moves in the medtech space — a 30% gain in August to $48.92 — and the Street is now scrambling to catch up. The most telling development…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ATRC — free to start on ORTEX.
Sign up for free →Open ATRC on ORTEX